The REACH-HFpEF Trial
Research type
Research Study
Full title
Randomised controlled trial of a facilitated home-based rehabilitation intervention in patients with heart failure with preserved ejection fraction and their caregivers: The REACH-HFpEF Trial
IRAS ID
298247
Contact name
Rod Taylor
Contact email
Sponsor organisation
NHS Greater Glasgow and Clyde
ISRCTN Number
ISRCTN47894539
Duration of Study in the UK
3 years, 5 months, 31 days
Research summary
This is an National Institute of Health Research (NIHR) Health Technology Assessment (HTA) Programme funded clinical trial aiming to find out whether a home-based rehabilitation programme in people with heart failure with preserved ejection fraction (or ’HFpEF’) and their caregivers is effective and cost-effective. Half of all people with heart failure have HFpEF. HFpEF is a complex condition of the heart that affects older individuals who typically have a number of concomitant diseases, including diabetes and high blood pressure. HFpEF has severe impacts on both patients and health care systems, including: a markedly reduced ability to undertake activities of daily living, greatly reduced quality of life, and highly increased risk of unplanned hospital admissions, resulting in high NHS costs. Drug and device therapies shown to work in people with the other type of heart failure (heart failure with reduced ejection fraction) don’t work in HFpEF. As a result, the 400,000 patients in the UK who have HFpEF are effectively living with untreated heart failure, with potentially devastating consequences for themselves and their families.
With prior National Institute for Health Research funding, we (1) designed a home-based rehabilitation intervention to promote physical and mental well-being and support self-management for people with heart failure and their caregivers: ‘REACH-HF’; (2) found in UK multicentre randomised controlled trial that REACH-HF is safe, clinically effective, and cost-effective in people with heart failure with reduced ejection fraction heart failure (HFrEF) and (3) shown in single centre randomised controlled trial that that REACH-HF is clinically effective and cost-effective in people with heart failure with HFpEF that REACH-HF is acceptable to patients and healthcare staff and the trial design acceptable and feasible
REC name
West of Scotland REC 3
REC reference
21/WS/0085
Date of REC Opinion
8 Sep 2021
REC opinion
Further Information Favourable Opinion